- RecruitingPHASE1, PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
This study looks at a new drug, surzetoclax, for multiple myeloma that has come back or not responded to other treatments. It checks how safe it is and how well it works, sometimes alone and sometimes with other medicines. We're looking for adults with this type of myeloma.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
For: Multiple MyelomaUnited States · Australia · Austria - Not yet recruitingPHASE3
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination (Etentamig plus Pomalidomide) with standard treatments to see if it's safe and helps improve the disease.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
For: Multiple MyelomaUnited States · Australia · Israel - Active not recruitingPHASE1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, etentamig, along with existing cancer treatments for adults with multiple myeloma that has come back or isn't responding to treatment. We want to see how safe it is and if it helps reduce the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Germany - RecruitingPHASE1
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, etentamig, combined with iberdomide, for adults with multiple myeloma that has come back or not responded to previous treatments. It aims to see how safe the combination is and if it helps control the disease.
For: Multiple MyelomaUnited States · Australia · Canada